Quoin pharmaceuticals announces 50% enrollment in open label netherton syndrome clinical trial

Ashburn, va., may 24, 2023 (globe newswire) -- quoin pharmaceuticals ltd. (nasdaq: qnrx) (the “company” or “quoin”), a clinical stage, specialty pharmaceutical company focused on rare and orphan diseases, announces that its open label study evaluating qrx003 as a treatment for netherton syndrome has reached 50% enrollment.
QNRX Ratings Summary
QNRX Quant Ranking